id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S8084 R24706 |
Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 | Preeclampsia/ eclampsia | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.86 [0.03;115.45] C excluded (control group) |
0/4 0/7 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8075 R24646 |
Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 | Preeclampsia/ eclampsia | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 6.14 [0.10;363.16] C | 0/4 0/22 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8146 R25046 |
Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 | Preeclampsia | early pregnancy | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.31 [0.58;3.00] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8142 R25018 |
Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 | Preeclampsia | early pregnancy | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.53 [0.70;3.35] | -/- 53,634/1,440,631 | 53,625 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.61 [0.75;3.47] | 53,625 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8146, 8084